ProCE Banner Activity

Simplified HCV Screening and Care in People Who Use Drugs

Podcast Episodes

In this episode, Drs. Trooskin and Sulkowski, along with patient advocate Ronni Marks, discuss how to overcome barriers to HCV testing and treatment in the priority population of people who use drugs. Listen as they discuss the strategy of extending care to where people who use drugs  are already receiving other services.

Released: December 24, 2024

Expiration: December 23, 2025

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with the Asian Health Foundation, Hepatitis B Foundation, and HealthHCV

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

AHF

ProCE Banner

Health HCV

ProCE Banner

Hepatitis B Foundation

ProCE Banner

Disclosure

Primary Author

Ronni Marks

Founder/Director, The Hepatitis C Mentor and Support Group (HCMSG)
Patient Advocate
New York, New York

Ronni Marks has no relevant financial relationships to disclose.

Mark S. Sulkowski, MD, FIDSA, FAASLD

Professor of Medicine
Director, Division of Infectious Diseases Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, FIDSA, FAASLD: consultant/advisor/speaker: AbbVie, Gilead, GlaxoSmithKline; data and safety monitoring board: Gilead.

Stacey B. Trooskin, MD, PhD, MPH

Executive Medical Officer
Mazzoni Center
Faculty, University of Pennsylvania
Perelman School of Medicine
Philadelphia, Pennsylvania

Stacey B. Trooskin, MD, PhD, MPH: researcher: Gilead Sciences.